Skip to main content
IonOpticks banner
IonOpticks logo

IonOpticks

IonOpticks develops, manufactures and distributes proteomics tools.

Backed by

Adelis Equity PartnersAdelis Equity Partners

EQUITY on September 10, 2024

About

IonOpticks designs and manufactures high-performance chromatography solutions that enhance LC-MS sensitivity for proteomics applications and ensure compatibility with major LC-MS platforms while scaling global operations and product commercialization.

Mission

IonOpticks designs and manufactures high-performance chromatography solutions to enhance LC-MS sensitivity for proteomics and related biological research. The company’s products are intended to improve discovery from biological samples across applications such as drug discovery, phosphoproteomics and shotgun proteomics. IonOpticks’ technology was developed at the Walter and Eliza Hall Institute (WEHI) and the company was incubated there for two years. The firm is focused on ensuring compatibility across major LC-MS platforms and on bringing new products to market. Management says the company will scale operations globally and expand closer to key markets to better serve customers and collaborators. Recent board additions aim to support commercialization and an ambitious program of product introductions.

Quick Facts

Founded

2017

Funding

EQUITY

Industry

Manufacturing, Medical Device

Team Size

1-10

Headquarters

Melbourne, Victoria, Australia

IonOpticks | Matchbox | Matchbox